Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis

Detalles Bibliográficos
Autores principales: Caocci, Giovanni, Mulas, Olga, Mantovani, Daniela, Costa, Alessandro, Galizia, Andrea, Barabino, Luca, Greco, Marianna, Murru, Roberta, La Nasa, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308065/
https://www.ncbi.nlm.nih.gov/pubmed/34302519
http://dx.doi.org/10.1007/s00277-021-04613-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308065/
https://www.ncbi.nlm.nih.gov/pubmed/34302519
http://dx.doi.org/10.1007/s00277-021-04613-w

Ejemplares similares